Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Protocol ID
AALL1731
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
New diagnosis
Location
NSW, VIC, WA, SA, NZ
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Open
Sites
John Hunter Children's Hospital
Monash Children's Hospital
Perth Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Monash Children's Hospital
Perth Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
1 year to 31 Years
International registry ID's
NCT03914625
| Study Title | A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) |
|---|---|
| Protocol ID | AALL1731 |
| Disease (Sub Disease) | Leukaemia (ALL) |
| Diagnosis Stage | New diagnosis |
| Location | NSW / VIC / WA / SA / NZ |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT03914625 |
| Trial Status | Open |
| Trial Open Date | 15/10/2019 |
| Sites | John Hunter Children's Hospital / Monash Children's Hospital / Perth Children's Hospital / Women's & Children's Hospital / Christchurch Hospital / |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 1 year to 31 Years |
| International registry ID's | NCT03914625 |